The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Barsukov A.V.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Tyrenko V.V.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Gordienko A.V.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Rygman N.N.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Gulyaev N.I.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Koltsov A.V.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Tupitsyn V.V.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Bobrov A.L.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Tatarkin A.A.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Solovyev M.V.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Seidova A.Yu.

«Medical Military Academy named after S.M. Kirov» Ministry of Defence of Russian Federation, Saint-Petersburg, Russia

Acute decompensated heart failure with preserved ejecton fraction: focus on serelaxin

Authors:

Barsukov A.V., Tyrenko V.V., Gordienko A.V., Rygman N.N., Gulyaev N.I., Koltsov A.V., Tupitsyn V.V., Bobrov A.L., Tatarkin A.A., Solovyev M.V., Seidova A.Yu.

More about the authors

Read: 1609 times


To cite this article:

Barsukov AV, Tyrenko VV, Gordienko AV, et al. . Acute decompensated heart failure with preserved ejecton fraction: focus on serelaxin. Russian Journal of Cardiology and Cardiovascular Surgery. 2017;10(1):26‑33. (In Russ.)
https://doi.org/10.17116/kardio2017101226-33

Recommended articles:

References:

  1. Gulyaev N, Gordienko AV, Kuznetsov VV, et al. Modern viewson the pathogenetic mechanismsof endothelial dysfunctionin patients withaortic stenosiscalcining. Vestnik of Russian Military medical Academy. 2015;(3):210-216. (In Russ.).
  2. Seidov AYu, Barsukov VA. Gender-relatedfeatures of the main types of metabolismand proinflammatorystatusin individuals with hypertensionhavingdiastolic dysfunctionof the left ventricle / RCJ. 2016; 4(132): 75.
  3. SerdyukovD. Y., GordienkoA.V.,Nikiforov V.S., et al.Clinical and ultrasound predictors of heart failure in patients in the subacute period of myocardial infarction. RCJ. 2012;2:16-20. (In Russ.).
  4. Timofeev AB, Schegolev AV, Rysman NN. Modern approaches tothe treatment of heart failurein acute myocardial infarction. Vestnik of anesthesiology and resuscitation. 2014;(1):68-75. (In Russ.).
  5. Shcherbatyuk OV, Turenko VV, Belevitin AB, Svistov AS. Brain natriuretic peptide genetic code of heart failure. Vestnik of Russian Military medical Academy. 2006;2:100-107. (In Russ.).
  6. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev. 2007;12:91-95.
  7. Banerjee P, Clark AL, Nikitin N, Cleland JG. Diastolic heart failure. Paroxysmal or chronic? Eur J Heart Fail. 2004;6:427-431.
  8. Bishu K, Deswal A, Chen HH, LeWinter MM, Lewis GD, Semigran MJ, Borlaug BA, McNulty S, Hernandez AF, Braunwald E, Redfield MM. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012;164:763-770. doi:10.1016/j.ahj.2012.08.014
  9. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34:1424-1431. doi:10.1093/eurheartj/eht066
  10. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.
  11. Cotter G, Milo O, Davison BA. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond. Curr Heart Fail Rep. 2014;11:19-30.
  12. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781-791.
  13. Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J. 2014;35:1041-1050.
  14. Fonarow GC, Stough WG, Abraham WT, et al. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768-777.
  15. Gheorghiade M, Konstam MA, Burnett JCJr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
  16. Goldberg RJ, Gurwitz JH, Saczynski JS, et al. Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]). Am J Cardiol. 2013;111:1324-1329.
  17. Massie BM, Carson PE, McMurray JJ. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
  18. Massie BM, Carson PE, McMurray JJ. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
  19. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
  20. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized Trial. JAMA. 2007;297:1883-1891.
  21. Metaanalysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data metaanalysis. Eur Heart J. 2012;33:1750-1757.
  22. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196-206.
  23. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
  24. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277.
  25. Summers RL, Amsterdam E. Pathophysiology of acute decompensated heart failure. Heart Fail Clin. 2009;5:9-17.
  26. Teerlink JR, Cotter G, Davison BA et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomized, placebo-controlled trial. Lancet. 2013;381:29-39.
  27. Teichman SL, Unemori E, Teerlink JR. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7:75-82.
  28. Yancy CW, Lopatin M, Stevenson LW, et al. ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76-84.
  29. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.